Essential Partners’s RAPT Therapeutics RAPT Stock Holding History

Essential Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$8	–	2764
2025 Q2	$8	Buy	+1	New	+$8	﹤0.01%	2257

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Boone Capital Management Atlanta, Georgia $428M AUM 136.02% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Essential Partners's RAPT Position: Q3 2025 in Review

Essential Partners sold out of RAPT Therapeutics (RAPT) in Q3 2025, closing a stake of 1 share — an estimated $8 sold.

Essential Partners first reported a position in RAPT in Q2 2025 and held it in 1 quarter. The position peaked at $8 in Q2 2025. 65 funds tracked by Wall St. Rank hold RAPT as of Q3 2025.

Essential Partners reported no remaining RAPT Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 1 RAPT Therapeutics share in Q3 2025, an estimated $8.
Essential Partners first reported a position in RAPT Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's RAPT Therapeutics position peaked at $8 in Q2 2025.
65 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.